What are the guidelines for use of anticoagulation in patients with Osler-Weber-Rendu disease (OWRD) (hereditary hemorrhagic telangiectasia [HHT])?

Updated: Oct 06, 2020
  • Author: Klaus-Dieter Lessnau, MD, FCCP; Chief Editor: Vincent Lopez Rowe, MD  more...
  • Print
Answer

Provide HHT patients with anticoagulation (prophylactic or therapeutic) or antiplatelet therapy when there is an indication, with individualized bleeding risks taken into consideration; bleeding in HHT is not an absolute contraindication for these therapies.

Where possible, avoid the use of dual antiplatelet therapy (DAPT) and/or a combination of antiplatelet therapy and anticoagulation.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!